Alphanine SD Market Report 2026

Alphanine SD Market Overview

• The Alphanine SD market growth in the historic period has been driven by established treatment for hemophilia b, plasma derived factor availability • Market expansion is supported by growing hemophilia diagnosis rates, expansion of prophylactic therapy use • Growth Driver: Growing Hemophilia Prevalence Drives Alphanine SD Market Growth Through Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Alphanine SD Market?

Alphanine SD is a high-purity, freeze-dried Factor IX concentrate derived from human plasma, specifically designed to treat hemophilia B by replacing the deficient clotting factor. It is used to control and prevent bleeding episodes, manage perioperative bleeding, and provide routine prophylaxis in individuals with hemophilia B. The main product types in alphanine SD are plasma derived factor IX concentrates and recombinant factor IX products. Plasma-derived factor IX concentrates are purified blood plasma-derived products used to treat factor IX deficiencies. In the Alphanine SD market, they help manage and treat bleeding disorders such as hemophilia B effectively. Offered in formulations such as lyophilized powder and intravenous solutions. It is indicated for clinical uses such as hemophilia B, inhibitor management, bleeding episodes, and surgical prophylaxis. Additionally, it is designed for use in adults, pediatric, and geriatric patients.

What Is The Alphanine SD Market Growth Forecast?

The growth in the forecast period can be attributed to growing hemophilia diagnosis rates, expansion of prophylactic therapy use, increasing surgical interventions, stable plasma supply, demand in emerging healthcare markets. Major trends in the forecast period include continued use of plasma derived clotting factors, demand for hemophilia b prophylaxis, hospital based bleeding management, preference for high purity factor IX, use in surgical bleeding control.

Global Alphanine SD Market Segmentation

1) By Product Type: Plasma Derived Factor IX Concentrates, Recombinant Factor IX Products 2) By Formulation: Lyophilized Powder, Intravenous Solutions 3) By Clinical Indication: Hemophilia B, Inhibitor Management, Bleeding Episodes, Surgical Prophylaxis 4) By End Users: Adult, Pediatric, Geriatric

What Are The Drivers Of The Alphanine SD Market?

The growing prevalence of hemophilia is expected to propel the growth of the alphanine SD market going forward. Hemophilia is a rare, inherited bleeding disorder where the blood does not clot properly due to the absence or deficiency of certain clotting factors such as VIII and IX. The increasing prevalence of hemophilia is influenced by enhanced diagnostic capabilities, better awareness campaigns, improved healthcare infrastructure, and longer life expectancy due to advanced treatments. Alphanine SD contributes to addressing hemophilia B by offering targeted treatment options that support effective management, and improving patient outcomes as advancements in diagnosis, reporting, and awareness drive an increase in identified cases. For instance, in October 2025, according to the report published by World Federation of Hemophilia (WFH), a Canada-based non-profit organization, as of 2024, there were 271,918 identified patients with hemophilia worldwide, including 224,353 with Hemophilia A and 45,600 with Hemophilia B. Therefore, the growing prevalence of hemophilia is driving the alphanine SD industry. The rise in healthcare expenditure is expected to propel the growth of the alphanine SD market going forward. Healthcare expenditure refers to the total amount of financial resources spent on medical services, healthcare infrastructure, pharmaceuticals, and healthcare-related activities. Healthcare expenditure is rising due to factors such as an aging population, increasing prevalence of chronic and lifestyle-related diseases, advances in medical technology, and greater access to healthcare services. Alphanine SD contributes to increased healthcare expenditure due to the costs associated with its continuous prophylactic use, management of bleeding episodes, and related healthcare services for hemophilia B. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, the rise in healthcare expenditure is driving the alphanine SD industry. The rising aging population is expected to drive the alphanine SD market going forward. The aging population refers to the segment of the population characterized by an increasing number of individuals aged 65 and older, typically resulting from higher life expectancy and lower birth rates. The aging population is driven by advancements in healthcare, medical technology, improved living conditions, and longer life expectancy. Alphanine SD is essential for the aging population as it offers an effective treatment for bleeding disorders, helping to manage and mitigate health issues related to blood clotting in older adults. This contributes to improved overall health outcomes, enhanced quality of life, and a reduced risk of complications associated with hemophilia and other clotting deficiencies, enabling older individuals to maintain better health and independence. For instance, in October 2025, according to World Health Organization, a Switzerland based health organization, it is anticipated that the by 2030, 1 in 6 people in the world will be aged 60 years or over. Additionally, by 2050, the world’s population of people aged 60 years and older will double (2.1 billion). Therefore, the rising aging population is driving the alphanine SD industry.

Key Players In The Global Alphanine SD Market

Major companies operating in the alphanine sd market are Grifols SA

Regional Insights

North America was the largest region in the alphanine SD market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Alphanine SD Market?

The alphanine SD market consists of sales of infusion devices, dilution kits, and prophylactic products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Alphanine SD Market Report 2026?

The alphanine sd market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the alphanine sd industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.